On Jul. 9, the Partnership to Improve Patient Care held a webinar to discuss the implications of the Institute for Clinical and Economic Review's assessment on treatments for the novel coronavirus (COVID-19). COVID-19 has presented an unprecedented challenge for our society. It has taken its toll on our health care system and ground much of society to a halt. It has also presented unique challenges for the patient and disability community that are at higher risk for complications should they contract the disease along with the added burden of attempts in many states to implement discriminatory crisis standards that would deny them care in a shortage.
In the midst of this, ICER has released a model for determining the “value” of treatments for COVID-19. ICER has made clear they intend to continue using this model for future new treatments, making it seminally important that we understand the model and what it could mean for COVID-19 treatment access and future treatment development should it be relied on by policymakers and payers. Click here to view the slide presentation.